1.49
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMRA?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.5899
Offen:
$1.55
24-Stunden-Volumen:
11,452
Relative Volume:
0.80
Marktkapitalisierung:
$4.60M
Einnahmen:
$4.33M
Nettoeinkommen (Verlust:
$-4.17M
KGV:
-0.9965
EPS:
-1.4953
Netto-Cashflow:
$-3.19M
1W Leistung:
-5.99%
1M Leistung:
-15.34%
6M Leistung:
-37.26%
1J Leistung:
-54.01%
Biomerica Inc Stock (BMRA) Company Profile
Firmenname
Biomerica Inc
Sektor
Branche
Telefon
(949) 379-2875
Adresse
17571 VON KARMAN AVENUE, IRVINE, CA
Compare BMRA vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
BMRA
Biomerica Inc
|
1.49 | 5.01M | 4.33M | -4.17M | -3.19M | -1.4953 |
|
ABT
Abbott Laboratories
|
105.74 | 182.00B | 46.59B | 5.41B | 7.38B | 3.0938 |
|
SYK
Stryker Corp
|
325.74 | 129.09B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
MDT
Medtronic Plc
|
85.40 | 107.81B | 36.36B | 4.84B | 5.43B | 3.7261 |
|
BSX
Boston Scientific Corp
|
46.73 | 67.64B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
86.03 | 47.81B | 6.30B | 1.07B | 1.09B | 1.8406 |
Biomerica Inc Stock (BMRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-11-10 | Eingeleitet | Colliers Securities | Buy |
| 2018-01-04 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Biomerica Inc Aktie (BMRA) Neueste Nachrichten
BMRA|Biomerica Inc|Price:1.620|Chg%:+0.035 - TradingKey
Biomerica Inc (BMRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Biomerica Inc (BMRA) Income Statement - TradingKey
Biomerica Inc (BMRA) Institutional Confidence - TradingKey
Biomerica Inc (BMRA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Biomerica Inc (BMRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Biomerica Inc (BMRA) Balance Sheet - TradingKey
Biomerica, Inc. Revenue Breakdown – NASDAQ:BMRA - TradingView
Biomerica Inc (BMRA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BMRA Q2 2026 Earnings: Pre-Revenue Diagnostics Firm Reports $0.44 Loss Per Share as Stock Holds Steady - dars.gov.et
BMRABiomerica Inc Short Interest - Finviz
Biomerica Inc. (BMRA) Q2 2026 Earnings: Negative EPS as Company Continues Operational FocusBanking Earnings Report - dars.gov.et
Price to sales forward of Biomerica, Inc. – NASDAQ:BMRA - TradingView
Enterprise value to EBITDA forward of Biomerica, Inc. – NASDAQ:BMRA - TradingView
Price to earnings forward of Biomerica, Inc. – NASDAQ:BMRA - TradingView
Biomerica Inc (BMRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Biomerica Inc (BMRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Biomerica | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
BMRA Q1 2026 Earnings: Net Loss Reported Amid Operational ChallengesFree Cash Flow Trends - dars.gov.et
Biomerica Inc (BMRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Biomerica Inc (BMRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Biomerica (BMRA) Slips Slightly to $2.05; Near Key Support Amid Quiet TradingDark Pool Volume - newsline.com
Biomerica (BMRA) Edges Lower, Testing Key Support at $1.95ETF Liquidity - newsline.com
Biomerica (BMRA) Edges Higher as Stock Holds Above Key Support LevelIV Contraction - newsline.com
BMRA Q1 2026 Earnings: Net Loss of $0.44 per Share; Stock Declines 0.92%Analyst Consensus Shift - newsline.com
Biomerica (BMRA) Slides Slightly as Stock Approaches Key Support LevelIceberg Order - newsline.com
Biomerica (BMRA) Q1 2026 Earnings: Narrowing Loss Amid Ongoing Operational ChallengesReturn On Capital - newsline.com
Biomerica, Inc. Announces $500,000 Securities Purchase Agreement and Secured Promissory Note – Form 8-K Filing, May 29, 2026 – Minichart - Minichart
Biomerica Enters Related-Party Deal to Boost Liquidity - TipRanks
Biomerica to Sell 6% Diagnosis Stake for $500,000; Issues 8% Note Pending Transfer - TradingView
Biomerica (BMRA) sells 6% Diagnosis S.A. stake to CEO-affiliated buyers - Stock Titan
Biomerica Inc. (BMRA) Sees Modest Gain as Shares Test Key ResistanceDip Buy Trade - newsline.com
BMRA Q1 2026 Earnings: Operating Loss Widens to $0.44 per Share as Pre-Revenue Biotech Advances Pipeline - newsline.com
Biomerica secures USD 1.75M contract for IVD diagnostic development - Medical Buyer
BMRA Stock Price, Quote & Chart | BIOMERICA INC (NASDAQ:BMRA) - ChartMill
Biomerica Inc. Awarded $1.75 Million Contract for IVD Product Development - geneonline.com
Biomerica (BMRA) Secures Master Services Agreement for Diagnosti - GuruFocus
Biomerica Inc. (BMRA) Holds Near Support Amid Modest PullbackBeta Neutral Pair - The Legal Advocate
Biomerica Wins $1.75M Contract to Develop Diagnostic Tests - Orange County Business Journal
Biomerica signs contract development deal worth over $1.75M By Investing.com - Investing.com Canada
Biomerica lands $1.75 million CDMO master services agreement for IVD diagnostic development - marketscreener.com
Biomerica signs contract development deal worth over $1.75M - Investing.com
Biomerica Lands a $1.75 Million CDMO Master Services Agreement for IVD Diagnostic Development - The Manila Times
Undisclosed $1.75M lab deal taps Biomerica’s diagnostic test expertise - Stock Titan
BMRA Q1 2026 Earnings: Loss of $0.44 Per Share Amid No Revenue DisclosureEarnings Preview - dars.gov.et
Biomerica Q1 2026 Earnings: Net Loss of $0.44 Per Share Amid Lack of Revenue DisclosureManagement Guidance Update - The Legal Advocate
Biomerica Inc. (BMRA) Q1 2026 Earnings: Negative EPS Persists Amid Pre-Revenue StageEarnings Season Review - The Legal Advocate
BMRA Q1 2026 Earnings: Biomerica Reports Net Loss of $0.44 Per Share Amid Ongoing Development Efforts - Newser
Finanzdaten der Biomerica Inc-Aktie (BMRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):